University of Massachusetts Center for Clinical and Translational Science

马萨诸塞大学临床与转化科学中心

• 批准号: 10642746
• 负责人: Katherine F Luzuriaga
• 金额: $ 514.51万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-14 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10642746
• 关键词: Abbreviations; Acceleration; Address; Advanced Development; Biological Products; Boston; Career Choice; Childhood; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communities; Community Health; Competence; Complex; Consultations; Data; Data Science; Decision Making; Development; Device or Instrument Development; Disparity population; Education; Elderly; Engineering; Ensure; Entrepreneurship; Environment; Evaluation; Fostering; Foundations; Funding; Future; Goals; Grant; Health; Health system; Healthcare; Human; Individual; Industry; Informatics; Institution; Knowledge; Learning; Life; Longevity; Massachusetts; Medical Device; Mentorship; Methods; Modeling; Multi-Institutional Clinical Trial; National Center for Advancing Translational Sciences; Operations Research; Participant; Patient Care; Patients; Performance; Point of Care Technology; Privacy; Process; Professional Practice; Program Development; Research; Research Personnel; Research Support; Resources; Safety; Science; Security; Services; Speed; System; Technology; Testing; Training; Training Programs; Translating; Translation Process; Translational Research; Translations; Underrepresented Populations; Underserved Population; United States National Institutes of Health; Universities; Vision; Workforce Development; career development; clinical center; clinical trial recruitment; commercialization; community engagement; cost effective; cultural competence; data lake; didactic education; digital; evidence base; first-in-human; flexibility; health care delivery; health equity; hearing impairment; improved; innovation; insight; interoperability; literacy; medical schools; member; new product development; next generation; novel; novel strategies; participant enrollment; population health; programs; recruit; safety net; simulation; skills; success; translational impact; translational pipeline; translational research program; vision science

Contact PD/PI: Luzuriaga, Katherine PROJECT SUMMARY/ABSTRACT – O. OVERALL The UMCCTS was organized in 2006 and NIH-funded in 2010 (renewed 2015), with the vision of improving health and health care delivery by advancing the science of translation, by catalyzing high-quality research across the translational spectrum, and by building and supporting a robust translational workforce. Our overarching goal is to speed the development of new products and approaches to advance patient care and community health. As Massachusetts’ only public university system (UMass) partnered with 2 of the state’s safety net clinical systems (UMass Memorial Health Care, UMMHC; Baystate Health), we share an enduring focus on public engagement and societal benefit. The UMCCTS engages a broad range of stakeholders (communities, patient groups, foundations, industry, NCATS and CTSA hubs) to ensure that the research we support and workforce we train address problems important to the communities we serve. With our partners, we identify important problems and needs, develop and validate enabling platforms, provide resources that facilitate transdisciplinary team science, and educate the next generation of investigators. We use data and analytics to generate knowledge, apply that knowledge to improve performance, then use lessons learned to inform and refine the next improvement cycle. UMCCTS Workforce Development programs ensure the future sustainability of the clinical and translational research (CTR) enterprise. Our 5 Specific Aims correspond to the 5 NCATS strategic goals stated in the NCATS FOA and build on our prior successes: Aim 1: Workforce Development: Build and support a transdisciplinary CTR workforce with the knowledge, skills, and institutional environment to advance high-impact translational research; Aim 2: Collaboration/Engagement: Engage stakeholders throughout the translational process to optimize evidence- based, community-integrated research practices and apply these practices to specific projects that improve individual and population health; Aim 3: Integration Across the Lifespan & Underrepresented or Disadvantaged Populations: Improve insights and practices that ensure that discoveries are translated to all who might benefit; Aim 4: Methods & Processes: Develop, test, and share innovative solutions to critical gaps in the translational research process from discovery to community; Aim 5: Informatics: Develop, demonstrate, and disseminate informatics innovations that accelerate both translational science and translational research operations and that provide the essential evidence base for learning health systems. Abbreviations: CECC - Community Engagement and Collaboration Core; CRPG - Clinical Research Professionals Group; D3Health - Center for Data-Driven Discovery in Health Care; PEPP - Preparing Engineers for Professional Practice; SPRC - Science Participation Research Center; TRAcs - Translational Research Accelerator; UMA - UMass Amherst; UMB - UMass Boston; UMD - UMass Dartmouth; UML - UMass Lowell; UMMHC - UMass Memorial Healthcare; UMMS - UMass Medical School Page 185 Project Summary/Abstract Contact PD/PI: Luzuriaga, Katherine

联系人 PD/PI：Luzuriaga、Katherine 项目概要/摘要 – O. 总体 UMCCTS 成立于 2006 年，并于 2010 年获得 NIH 资助（2015 年更新），其愿景是改善 通过推进翻译科学、促进高质量研究来提供健康和医疗保健 跨越翻译领域，并建立和支持强大的翻译团队。 总体目标是加快新产品和新方法的开发，以促进患者护理和 作为马萨诸塞州唯一的公立大学系统 (UMass)，该系统与该州的 2 所大学合作。 安全网临床系统（UMass Memorial Health Care、UMMHC；Baystate Health），我们拥有持久的 UMCCTS 注重公众参与和社会效益，吸引了广泛的利益相关者。 （社区、患者团体、基金会、行业、NCATS 和 CTSA 中心），以确保我们的研究 我们培训的支持和员工队伍与我们的合作伙伴一起解决对我们服务的社区重要的问题。 我们识别重要的问题和需求，开发和验证支持平台，提供资源 促进跨学科团队科学，并教育下一代研究人员。 分析产生知识，应用这些知识来提高绩效，然后利用吸取的经验教训 通知并完善下一个改进周期 UMCCTS 劳动力发展计划确保未来。 临床和转化研究 (CTR) 企业的可持续性。 我们的 5 个具体目标与 NCATS FOA 中规定的 5 个 NCATS 战略目标相对应，并以我们的 先前的成功经验： 目标 1：劳动力发展：建立并支持跨学科的 CTR 劳动力队伍 推动高影响力转化研究的知识、技能和制度环境；目标 2： 协作/参与：在整个转化过程中让利益相关者参与以优化证据- 基于社区的综合研究实践，并将这些实践应用到具体项目中，以改善 个人和人口健康；目标 3：终生融合和代表性不足或弱势群体 人群：提高洞察力和实践，确保将发现转化为所有可能受益的人； 目标 4：方法和流程：针对转化中的关键差距开发、测试和分享创新解决方案 从发现到社区的研究过程；目标 5：信息学：开发、演示和传播 加速转化科学和转化研究运作的信息学创新 这为学习卫生系统提供了重要的证据基础。 缩写：CECC - 社区参与和协作核心；CRPG - 临床研究； 专业团体；D3Health - 医疗保健数据驱动发现中心 - 准备； 专业实践工程师；SPRC - 科学参与研究中心； 研究加速器；UMA - 麻省大学阿默斯特分校；UMD - 麻省大学达特茅斯分校； 麻省大学洛厄尔分校；UMHC - 麻省大学纪念医疗中心； 第185页 项目概要/摘要 联系人 PD/PI：Luzuriaga、Katherine

项目成果

Platelets and COVID-19: Inflammation, Hyperactivation and Additional Questions.

• DOI: 10.1161/circresaha.120.318218
• 发表时间: 2020-11-06
• 期刊: Circulation research
• 影响因子: 20.1
• 作者: Koupenova M;Freedman JE
• 通讯作者: Freedman JE

New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown.

• DOI: 10.46697/001c.17692
• 发表时间: 2020-11-03
• 期刊: AIB insights
• 作者: Dunlap D;Santos RS;McManus DD;Buchholz BO;Hafer NS;Picard M
• 通讯作者: Picard M

Cardiovascular health promotion and risk reduction in children and adolescents: the new integrated guidelines.

儿童和青少年的心血管健康促进和降低风险：新的综合指南。

• DOI: 10.1097/jcn.0b013e31824f173f
• 发表时间: 2012
• 期刊: The Journal of cardiovascular nursing
• 作者: Hayman,LauraL;Himmelfarb,CherylDennison
• 通讯作者: Himmelfarb,CherylDennison

PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans.

• DOI: 10.1126/scitranslmed.aay4145
• 发表时间: 2020-11-25
• 期刊: Science translational medicine
• 影响因子: 17.1
• 作者: Rojas-Rodriguez R;Ziegler R;DeSouza T;Majid S;Madore AS;Amir N;Pace VA;Nachreiner D;Alfego D;Mathew J;Leung K;Moore Simas TA;Corvera S
• 通讯作者: Corvera S

Postpartum Depression-New Screening Recommendations and Treatments.

产后抑郁症 - 新的筛查建议和治疗。

• DOI: 10.1001/jama.2023.21311
• 发表时间: 2023
• 期刊: JAMA
• 作者: MooreSimas,TiffanyA;Whelan,Anna;Byatt,Nancy
• 通讯作者: Byatt,Nancy